Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time.
Adult
Aged
Bile Acids and Salts
/ analysis
Chemokine CCL2
/ blood
Energy Metabolism
Fatty Acids, Volatile
/ analysis
Fecal Microbiota Transplantation
Feces
/ chemistry
Gastric Bypass
Gastrointestinal Microbiome
Gastrointestinal Transit
Gene Expression
Glucose
/ metabolism
Humans
Insulin Resistance
Lipolysis
Male
Metabolic Syndrome
/ metabolism
Metabolomics
Middle Aged
Subcutaneous Fat
/ metabolism
Tissue Donors
Young Adult
bile acid metabolism
diabetes mellitus
gastrointestinal transit
intestinal microbiology
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
18
01
2019
revised:
10
05
2019
accepted:
13
05
2019
pubmed:
31
5
2019
medline:
15
4
2020
entrez:
1
6
2019
Statut:
ppublish
Résumé
Bariatric surgery improves glucose metabolism. Recent data suggest that faecal microbiota transplantation (FMT) using faeces from postbariatric surgery diet-induced obese mice in germ-free mice improves glucose metabolism and intestinal homeostasis. We here investigated whether allogenic FMT using faeces from post-Roux-en-Y gastric bypass donors (RYGB-D) compared with using faeces from metabolic syndrome donors (METS-D) has short-term effects on glucose metabolism, intestinal transit time and adipose tissue inflammation in treatment-naïve, obese, insulin-resistant male subjects. Subjects with metabolic syndrome (n=22) received allogenic FMT either from RYGB-D or METS-D. Hepatic and peripheral insulin sensitivity as well as lipolysis were measured at baseline and 2 weeks after FMT by hyperinsulinaemic euglycaemic stable isotope ( We observed a significant decrease in insulin sensitivity 2 weeks after allogenic METS-D FMT (median rate of glucose disappearance: from 40.6 to 34.0 µmol/kg/min; p<0.01). Moreover, a trend (p=0.052) towards faster intestinal transit time following RYGB-D FMT was seen. Finally, we observed changes in faecal bile acids (increased lithocholic, deoxycholic and (iso)lithocholic acid after METS-D FMT), inflammatory markers (decreased adipose tissue chemokine ligand 2 (CCL2) gene expression and plasma CCL2 after RYGB-D FMT) and changes in several intestinal microbiota taxa. Allogenic FMT using METS-D decreases insulin sensitivity in metabolic syndrome recipients when compared with using post-RYGB-D. Further research is needed to delineate the role of donor characteristics in FMT efficacy in human insulin-resistant subjects. NTR4327.
Identifiants
pubmed: 31147381
pii: gutjnl-2019-318320
doi: 10.1136/gutjnl-2019-318320
pmc: PMC7034343
doi:
Substances chimiques
Bile Acids and Salts
0
CCL2 protein, human
0
Chemokine CCL2
0
Fatty Acids, Volatile
0
Glucose
IY9XDZ35W2
Banques de données
NTR
['NTR4327']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
502-512Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MN is in the Scientific Advisory Board of Caelus Pharmaceuticals, the Netherlands. FB is in the Scientific Advisory Board of MetaboGen, Sweden.
Références
Nat Med. 2018 Oct;24(10):1526-1531
pubmed: 30150717
Microbiome. 2018 May 15;6(1):89
pubmed: 29764499
Gastroenterology. 2012 Oct;143(4):913-6.e7
pubmed: 22728514
J Pharm Biomed Anal. 2013 Jun;80:107-15
pubmed: 23542733
Nat Rev Endocrinol. 2014 Aug;10(8):488-98
pubmed: 24821328
Cell. 2014 Nov 6;159(4):789-99
pubmed: 25417156
Diabetes Care. 2015 Aug;38(8):1567-82
pubmed: 26421334
Front Immunol. 2016 Mar 31;7:125
pubmed: 27065209
Nat Commun. 2015 Jul 02;6:7629
pubmed: 26134028
Cell Metab. 2015 Aug 4;22(2):228-38
pubmed: 26244932
Sci Rep. 2017 Mar 27;7(1):441
pubmed: 28348415
Nat Commun. 2017 Oct 10;8(1):845
pubmed: 29018189
Science. 2013 Sep 6;341(6150):1241214
pubmed: 24009397
Am J Clin Nutr. 2009 Nov;90(5):1244-51
pubmed: 19776143
Nature. 2006 Dec 21;444(7122):1027-31
pubmed: 17183312
Cell Metab. 2013 Feb 5;17(2):225-35
pubmed: 23395169
Gastroenterology. 1987 Jan;92(1):40-7
pubmed: 3023168
Environ Microbiol. 2009 Oct;11(10):2574-84
pubmed: 19601958
Biochem J. 1981 Aug 15;198(2):353-6
pubmed: 7034729
Cell Metab. 2017 Oct 3;26(4):611-619.e6
pubmed: 28978426
Nature. 2006 Dec 21;444(7122):1022-3
pubmed: 17183309
Endocr Rev. 2018 Apr 1;39(2):133-153
pubmed: 29309555
Cell. 2018 Nov 1;175(4):947-961.e17
pubmed: 30401435
Nature. 2009 Jan 22;457(7228):480-4
pubmed: 19043404
Nutr Diabetes. 2015 Jun 15;5:e159
pubmed: 26075636
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Sci Transl Med. 2013 Mar 27;5(178):178ra41
pubmed: 23536013
Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310-9
pubmed: 24284963
Cell. 2015 Nov 19;163(5):1079-1094
pubmed: 26590418
Cell Metab. 2015 Oct 6;22(4):658-68
pubmed: 26321659
Am J Physiol Endocrinol Metab. 2015 Aug 15;309(4):E398-408
pubmed: 26126684
Curr Diab Rep. 2018 Jun 21;18(8):55
pubmed: 29931613
Ann Transl Med. 2013 Jul 1;1(2):14
pubmed: 24432301
Nat Genet. 2019 Apr;51(4):600-605
pubmed: 30778224
Nature. 2013 Jun 6;498(7452):99-103
pubmed: 23719380
J Clin Endocrinol Metab. 2016 Aug;101(8):3002-9
pubmed: 27270475
Cell Metab. 2016 Aug 9;24(2):341
pubmed: 27508877
Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E958-69
pubmed: 27094034
Sci Rep. 2017 Sep 20;7(1):11955
pubmed: 28931850
J Physiol. 2014 Jul 15;592(14):2943-50
pubmed: 24614746